Gene · 2217
Papers4,523
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
341 to 360 of 4,523
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Efficacy of FcRn antagonist efgartigimod in the treatment of Miller-Fisher/Guillain-Barré overlap syndrome: Two case reports. | J Neuroimmunol | 2025 | 40779911 | PubTator, text mining | PubMed |
| Nipocalimab: First Approval. | Drugs | 2025 | 40779124 | PubTator, text mining | PubMed |
| Single-cell atlas reveals heterogeneous response to FcRn blockade in anti-AChR antibody-positive generalised myasthenia gravis. | Clin Transl Med | 2025 | 40770830 | PubTator, text mining | PubMed |
| Patterns and functional consequences of antibody speciation in maternal-fetal transfer of coronavirus-specific humoral immunity. | PLoS Pathog | 2025 | 40768518 | PubTator, text mining | PubMed |
| Adding the FcRn antagonist efgartigimod for the prevention of IgG-mediated complications in the peri-transplant period. | Transfusion | 2025 | 40765182 | PubTator, text mining | PubMed |
| [Targeting neonatal Fc receptor blockade: reshaping the treatment landscape for IgG-mediated autoimmune diseases]. | Zhonghua Yi Xue Za Zhi | 2025 | 40764090 | PubTator, text mining | PubMed |
| Efgartigimod following plasma exchange in the treatment of subjects with generalised myasthenia gravis: study protocol for a multicentre, three-arm, open-label study. | BMJ Neurol Open | 2025 | 40761829 | PubTator, text mining | PubMed |
| Efgartigimod as a Fast-Acting Add-On Therapy in Antibody-Mediated Autoimmune Encephalitis. | Eur J Neurol | 2025 | 40755087 | PubTator, text mining | PubMed |
| Unknown Immunoregulatory Effects of FcRn Inhibition by Efgartigimod in Myasthenia Gravis: A New Mechanism of Action Beyond IgG Reduction. | Neurol Neuroimmunol Neuroinflamm | 2025 | 40743488 | PubTator, text mining | PubMed |
| Differentiation of HL-60 cells into primed neutrophils for the evaluation of antiapoptotic effects of poorly soluble nanoparticles. | PLoS One | 2025 | 40737277 | PubTator, text mining | PubMed |
| Beyond the first breath: comprehensive respiratory syncytial virus prevention through maternal immunization and infant immunoprophylaxis. | Asian Biomed (Res Rev News) | 2025 | 40735667 | PubTator, text mining | PubMed |
| Comment on: "Emergent role of complement inhibitors in myasthenic crisis - Complement for crisis, FcRn for continuity". | Clin Neurol Neurosurg | 2025 | 40729981 | PubTator, text mining | PubMed |
| Advanced human FcRn knock-in mice for pharmacokinetic profiling of therapeutic antibodies. | Sci Rep | 2025 | 40715281 | PubTator, text mining | PubMed |
| Response to comment on: "Emergent role of complement inhibitors in myasthenic crisis - Complement for crisis, FcRn for continuity (CNN-D-25-2177)". | Clin Neurol Neurosurg | 2025 | 40706350 | PubTator, text mining | PubMed |
| Advances in Peptidomimetics for Next-Generation Therapeutics: Strategies, Modifications, and Applications. | Chem Rev | 2025 | 40698392 | PubTator, text mining | PubMed |
| Single-chain Fab chain-exchange (scFab-PACE) converts targeted prodrugs into functional T cell engagers on tumor cells. | J Biol Chem | 2025 | 40680840 | PubTator, text mining | PubMed |
| AChR Autoantibody Pathogenic Properties Are Heterogeneously Distributed and Undergo Temporal Changes Among Patients With Myasthenia Gravis. | Neurol Neuroimmunol Neuroinflamm | 2025 | 40680247 | PubTator, text mining | PubMed |
| Functional characterization of DPP4 and FcRn as receptor and coreceptor for classical human astroviruses in Caco-2 cells. | PLoS Pathog | 2025 | 40680075 | PubTator, text mining | PubMed |
| Advancements in Autoimmune Hemolytic Anemia (AIHA) treatment: Exploring emerging therapies. | Leuk Res | 2025 | 40669399 | PubTator, text mining | PubMed |
| Editorial: Application of PKPD modeling in drug discovery and development. | Front Pharmacol | 2025 | 40642005 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2217/papers?page=18